ABSTRACT
alpha(1) Adrenergic receptors mediate both vascular and lower urinary tract tone, and alpha(1) receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified, with the alpha(1A) receptor being most prevalent in lower urinary tract tissue. This paper explores 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 amide as selective alpha(1A) receptor subtype antagonists. In receptor binding assays, these types of compounds generally display K(i) values for the alpha(1a) receptor subtype <1 nM while being greater than 100-fold selective versus the alpha(1b) and alpha(1d) receptor subtypes. Many of these compounds were also evaluated in vivo and found to be more potent than terazosin in both a rat model of prostate tone and a dog model of intra-urethral pressure without significantly affecting blood pressure. While many of the compounds tested displayed poor pharmacokinetics, compound 48 was found to have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the alpha(1a) over the alpha(1b) and alpha(1d) receptors as well as its favorable pharmacokinetic profile, 48 has the potential to relieve the symptoms of BPH without eliciting effects on the cardiovascular system.
Subject(s)
Adrenergic alpha-Antagonists/chemical synthesis , Pyrimidinones/chemical synthesis , Receptors, Adrenergic, alpha-1/drug effects , Adrenergic alpha-Antagonists/chemistry , Adrenergic alpha-Antagonists/pharmacokinetics , Adrenergic alpha-Antagonists/pharmacology , Animals , Biological Availability , Caco-2 Cells , Crystallography, X-Ray , Dogs , Humans , Male , Prostatic Hyperplasia/drug therapy , Pyrimidinones/chemistry , Pyrimidinones/metabolism , Pyrimidinones/pharmacology , Radioligand Assay , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic, alpha-1/metabolism , Structure-Activity RelationshipABSTRACT
A series of 3-(arylureido)-5-phenyl-1,4-benzodiazepines, nonpeptidal antagonists of the peptide hormone cholecystokinin (CCK), are described. Derived by reasoned modification of the CCK-A selective 3-carboxamido-1,4-benzodiazepine, MK-329, this paper chronicles the development of potent, orally effective compounds in which selectivity for the CCK-B receptor subtype was achieved. The principal lead structure that emerged from these studied is L-365,260, a compound which has been submitted for clinical evaluation. Details of the ability to modulate the receptor interactions of these benzodiazepines by appropriate structure modifications are discussed which imply the possibility of further refining the CCK-B receptor affinity and selectivity of this class of compounds.
Subject(s)
Benzodiazepines/chemical synthesis , Benzodiazepinones/chemical synthesis , Phenylurea Compounds , Receptors, Cholecystokinin/antagonists & inhibitors , Animals , Benzodiazepines/pharmacokinetics , Benzodiazepines/pharmacology , Benzodiazepinones/chemistry , Benzodiazepinones/pharmacokinetics , Benzodiazepinones/pharmacology , Biological Availability , Cerebral Cortex/metabolism , Devazepide , Guinea Pigs , Molecular Structure , Pancreas/metabolism , Rats , Sincalide/metabolism , Structure-Activity RelationshipABSTRACT
Non-peptide antagonists of the peptide hormone oxytocin (OT) with nanomolar OT receptor affinities are described. These compounds incorporate novel amido- and amidoalkylcamphor variations to the lead structure L-366,509 (1) to achieve receptor affinity enhancements of 2-3 orders of magnitude over that compound. The new OT antagonist L-367,773 (35) is shown to be an orally bioavailable agent with good duration in vivo and to inhibit OT-stimulated uterine contractions effectively in several in vitro and in vivo models.
Subject(s)
Piperazines/chemical synthesis , Piperidines/pharmacology , Receptors, Oxytocin/antagonists & inhibitors , Spiro Compounds/chemical synthesis , Spiro Compounds/pharmacology , Animals , Binding Sites/drug effects , Female , Oxytocin/antagonists & inhibitors , Piperazines/chemistry , Piperazines/pharmacology , Piperidines/chemistry , Rats , Receptors, Oxytocin/metabolism , Spiro Compounds/chemistry , Structure-Activity RelationshipABSTRACT
The first nonpeptide antagonists of the neurohypophyseal hormone, oxytocin (OT) are described. Derivatives of the spiroindenepiperidine ring system, these compounds include L-366,509, an orally bioavailable OT antagonist with good in vivo duration. The potential use of these agents for treatment of preterm labor and their significance as new nonpeptide ligands for peptide receptors are discussed.
